loading...| Preferred Name | lipopolysaccharide | |
| Synonyms |
LPS |
|
| Definitions |
An endotoxin and biologically active component of the Gram-negative bacterial cell wall that is a Toll-like receptor 4 (TLR4) agonist with potential immunostimulatory activity. Upon internalization, lipopolysaccharide (LPS) activates TLR4 which in turn activates the NFkappaB pathway, in addition to mitogen-activated protein kinases signaling pathways. This leads to the release of proinflammatory cytokines and stimulates an innate immune response against vaccine antigens. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101788" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101788" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000732862 |
|
| altLabel |
LPS |
|
| cui |
C0023810 |
|
| DATE FIRST PUBLISHED |
2012-05-01 |
|
| Date last modified |
2012-05-31 |
|
| definition |
An endotoxin and biologically active component of the Gram-negative bacterial cell wall that is a Toll-like receptor 4 (TLR4) agonist with potential immunostimulatory activity. Upon internalization, lipopolysaccharide (LPS) activates TLR4 which in turn activates the NFkappaB pathway, in addition to mitogen-activated protein kinases signaling pathways. This leads to the release of proinflammatory cytokines and stimulates an innate immune response against vaccine antigens. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101788" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101788" NCI Thesaurus) |
|
| NCI ID |
C101788 |
|
| notation |
CDR0000732862 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
lipopolysaccharide |
|
| tui |
T109 |